Financhill
Buy
75

ABT Quote, Financials, Valuation and Earnings

Last price:
$130.50
Seasonality move :
3.49%
Day range:
$130.47 - $132.05
52-week range:
$99.71 - $132.50
Dividend yield:
1.7%
P/E ratio:
17.18x
P/S ratio:
5.48x
P/B ratio:
5.73x
Volume:
5M
Avg. volume:
6.7M
1-year change:
17.56%
Market cap:
$228B
Revenue:
$42B
EPS (TTM):
$7.65

Analysts' Opinion

  • Consensus Rating
    Abbott Laboratories has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $133.08, Abbott Laboratories has an estimated upside of 1.25% from its current price of $131.44.
  • Price Target Downside
    According to analysts, the lowest downside price target is $109.00 representing 100% downside risk from its current price of $131.44.

Fair Value

  • According to the consensus of 18 analysts, Abbott Laboratories has 1.25% upside to fair value with a price target of $133.08 per share.

ABT vs. S&P 500

  • Over the past 5 trading days, Abbott Laboratories has overperformed the S&P 500 by 2.07% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • Abbott Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • Abbott Laboratories has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Abbott Laboratories reported revenues of $11B.

Earnings Growth

  • Abbott Laboratories has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Abbott Laboratories reported earnings per share of $5.27.
Enterprise value:
235.4B
EV / Invested capital:
--
Price / LTM sales:
5.48x
EV / EBIT:
31.47x
EV / Revenue:
5.61x
PEG ratio (5yr expected):
0.13x
EV / Free cash flow:
36.29x
Price / Operating cash flow:
31.75x
Enterprise value / EBITDA:
22.73x
Gross Profit (TTM):
$23.2B
Return On Assets:
18.29%
Net Income Margin (TTM):
31.95%
Return On Equity:
14.78%
Return On Invested Capital:
24.77%
Operating Margin:
17.41%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-12-31 2023-12-31 2024-12-31 2023-12-31 2024-12-31
Income Statement
Revenue $43.7B $40.1B $42B $10.2B $11B
Gross Profit $24.5B $22.1B $23.2B $5.7B $6B
Operating Income $8.4B $6.5B $6.8B $1.8B $1.9B
EBITDA $12.1B $10.5B $10.4B $2.8B $2.5B
Diluted EPS $3.91 $3.26 $7.65 $0.91 $5.27
Period Ending 2020-12-31 2021-12-31 2022-12-31 2023-12-31 2024-12-31
Balance Sheet
Current Assets $20.4B $24.2B $25.2B $22.7B --
Total Assets $72.5B $75.2B $74.4B $73.2B --
Current Liabilities $11.9B $13.1B $15.5B $13.8B --
Total Liabilities $39.5B $39.2B $37.5B $34.4B --
Total Equity $33B $36B $36.9B $38.8B --
Total Debt $18.7B $18.1B $16.8B $14.7B --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations $10.3B $6.5B $8.7B $1.9B $2.7B
Cash From Investing -$1.8B -$2.9B -$2.3B -$634M -$594M
Cash From Financing -$8.1B -$6.5B -$5.6B -$2.3B -$1.6B
Free Cash Flow $8.5B $4.5B $6.5B $1.3B $2.1B
ABT
Sector
Market Cap
$228B
$43.5M
Price % of 52-Week High
99.2%
47.5%
Dividend Yield
1.7%
0%
Shareholder Yield
4.16%
-0.74%
1-Year Price Total Return
17.56%
-35.82%
Beta (5-Year)
0.746
0.753
Dividend yield:
1.7%
Annualized payout:
$2.20
Payout ratio:
21.47%
Growth streak:
11 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $129.70
200-day SMA
Buy
Level $111.97
Bollinger Bands (100)
Buy
Level 111.92 - 122.04
Chaikin Money Flow
Buy
Level 2B
20-day SMA
Buy
Level $124.27
Relative Strength Index (RSI14)
Buy
Level 69.12
ADX Line
Buy
Level 43.69
Williams %R
Sell
Level -7.2011
50-day SMA
Buy
Level $118.37
MACD (12, 26)
Buy
Level 4.08
25-day Aroon Oscillator
Buy
Level 56
On Balance Volume
Neutral
Level 1.3B

Financial Scores

Buy
Altman Z-Score (Annual)
Level (5.0701)
Buy
CA Score (Annual)
Level (0.2392)
Buy
Beneish M-Score (Annual)
Level (-2.4717)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.9842)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.

Stock Forecast FAQ

In the current month, ABT has received 13 Buy ratings 5 Hold ratings, and 0 Sell ratings. The ABT average analyst price target in the past 3 months is $133.08.

  • Where Will Abbott Laboratories Stock Be In 1 Year?

    According to analysts, the consensus estimate is that Abbott Laboratories share price will rise to $133.08 per share over the next 12 months.

  • What Do Analysts Say About Abbott Laboratories?

    Analysts are divided on their view about Abbott Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Abbott Laboratories is a Sell and believe this share price will drop from its current level to $109.00.

  • What Is Abbott Laboratories's Price Target?

    The price target for Abbott Laboratories over the next 1-year time period is forecast to be $133.08 according to 18 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.

  • Is ABT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for Abbott Laboratories is a Buy. 13 of 18 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ABT?

    You can purchase shares of Abbott Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Abbott Laboratories shares.

  • What Is The Abbott Laboratories Share Price Today?

    Abbott Laboratories was last trading at $130.50 per share. This represents the most recent stock quote for Abbott Laboratories. Yesterday, Abbott Laboratories closed at $131.44 per share.

  • How To Buy Abbott Laboratories Stock Online?

    In order to purchase Abbott Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Is Palantir Stock in a Bubble?
Is Palantir Stock in a Bubble?

Shares of AI and data analytics giant Palantir (NASDAQ:PLTR) have…

Stock Ideas

Buy
59
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
61
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 111x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
65
ATEX alert for Feb 12

Anterix [ATEX] is down 0.72% over the past day.

Buy
87
GDS alert for Feb 12

GDS Holdings [GDS] is up 0.32% over the past day.

Sell
30
SPSC alert for Feb 12

SPS Commerce [SPSC] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock